
Andrew W C Zannettino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5576547/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. Journal of Cell Science, 2003, 116, 1827-1835.	1.2	949
2	Multipotential human adiposeâ€derived stromal stem cells exhibit a perivascular phenotype in vitro and in vivo. Journal of Cellular Physiology, 2008, 214, 413-421.	2.0	507
3	OCT-1–mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood, 2006, 108, 697-704.	0.6	413
4	Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells. Blood, 2005, 105, 3793-3801.	0.6	341
5	Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood, 2007, 110, 4064-4072.	0.6	309
6	Concise Review: Mesenchymal Stromal Cells: Potential for Cardiovascular Repair. Stem Cells, 2008, 26, 2201-2210.	1.4	300
7	Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nature Communications, 2015, 6, 8983.	5.8	296
8	The therapeutic applications of multipotential mesenchymal/stromal stem cells in skeletal tissue repair. Journal of Cellular Physiology, 2009, 218, 237-245.	2.0	294
9	Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood, 2005, 105, 3127-3132.	0.6	266
10	Differential Cell Surface Expression of the STRO-1 and Alkaline Phosphatase Antigens on Discrete Developmental Stages in Primary Cultures of Human Bone Cells. Journal of Bone and Mineral Research, 1999, 14, 47-56.	3.1	252
11	Metabolism of vitamin D3 in human osteoblasts: Evidence for autocrine and paracrine activities of 1α,25-dihydroxyvitamin D3. Bone, 2007, 40, 1517-1528.	1.4	229
12	Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches. Blood, 2010, 116, 375-385.	0.6	228
13	<i>EZH2</i> and <i>KDM6A</i> Act as an Epigenetic Switch to Regulate Mesenchymal Stem Cell Lineage Specification. Stem Cells, 2014, 32, 802-815.	1.4	223
14	RANKL Expression Is Related to the Differentiation State of Human Osteoblasts. Journal of Bone and Mineral Research, 2003, 18, 1088-1098.	3.1	213
15	Elevated Serum Levels of Stromal-Derived Factor-1α Are Associated with Increased Osteoclast Activity and Osteolytic Bone Disease in Multiple Myeloma Patients. Cancer Research, 2005, 65, 1700-1709.	0.4	186
16	TWIST Family of Basic Helix-Loop-Helix Transcription Factors Mediate Human Mesenchymal Stem Cell Growth and Commitment. Stem Cells, 2009, 27, 2457-2468.	1.4	181
17	The proliferation and phenotypic expression of human osteoblasts on tantalum metal. Biomaterials, 2004, 25, 2215-2227.	5.7	179
18	A role for pericytes as microenvironmental regulators of human skin tissue regeneration. Journal of Clinical Investigation, 2009, 119, 2795-806.	3.9	178

#	Article	IF	CITATIONS
19	Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Research, 2003, 63, 5438-45.	0.4	177
20	Long-term imatinib therapy promotes bone formation in CML patients. Blood, 2008, 111, 2538-2547.	0.6	144
21	Implanted Adult Human Dental Pulp Stem Cells Induce Endogenous Axon Guidance. Stem Cells, 2009, 27, 2229-2237.	1.4	144
22	Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. Journal of Cellular Physiology, 2005, 204, 714-723.	2.0	141
23	Mesenchymal stem cells in human placental chorionic villi reside in a vascular Niche. Placenta, 2010, 31, 203-212.	0.7	136
24	The Nitrogen-Containing Bisphosphonate, Zoledronic Acid, Influences RANKL Expression in Human Osteoblast-Like Cells by Activating TNF-α Converting Enzyme (TACE). Journal of Bone and Mineral Research, 2004, 19, 147-154.	3.1	133
25	Characterisation and developmental potential of ovine bone marrow derived mesenchymal stem cells. Journal of Cellular Physiology, 2009, 219, 324-333.	2.0	132
26	An injectable hydrogel incorporating mesenchymal precursor cells and pentosan polysulphate for intervertebral disc regeneration. Biomaterials, 2013, 34, 9430-9440.	5.7	132
27	Enrichment for STROâ€1 expression enhances the cardiovascular paracrine activity of human bone marrowâ€derived mesenchymal cell populations. Journal of Cellular Physiology, 2010, 223, 530-540.	2.0	130
28	Dysregulation of bone remodeling by imatinib mesylate. Blood, 2010, 115, 766-774.	0.6	126
29	RANK Expression as a Cell Surface Marker of Human Osteoclast Precursors in Peripheral Blood, Bone Marrow, and Giant Cell Tumors of Bone. Journal of Bone and Mineral Research, 2006, 21, 1339-1349.	3.1	120
30	The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia, 2011, 25, 1533-1542.	3.3	117
31	A Novel Monoclonal Antibody (STRO-3) Identifies an Isoform of Tissue Nonspecific Alkaline Phosphatase Expressed by Multipotent Bone Marrow Stromal Stem Cells. Stem Cells and Development, 2007, 16, 953-964.	1.1	115
32	PSGL-1-Mediated Adhesion of Human Hematopoietic Progenitors to P-Selectin Results in Suppression of Hematopoiesis. Immunity, 1999, 11, 369-378.	6.6	109
33	Twist-1 Induces Ezh2 Recruitment Regulating Histone Methylation along the <i>Ink4A/Arf</i> Locus in Mesenchymal Stem Cells. Molecular and Cellular Biology, 2012, 32, 1433-1441.	1.1	106
34	The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. Bone, 2004, 34, 112-123.	1.4	104
35	Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone, 2001, 28, 370-377.	1.4	99
36	A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. Blood, 2019, 134, 30-43.	0.6	99

ANDREW W C ZANNETTINO

#	Article	IF	CITATIONS
37	Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability. Leukemia, 2019, 33, 457-468.	3.3	96
38	Potential Adhesion Mechanisms for Localisation of Haemopoietic Progenitors to Bone Marrow Stroma. Leukemia and Lymphoma, 1994, 12, 353-363.	0.6	92
39	Mesenchymal lineage precursor cells induce vascular network formation in ischemic myocardium. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, S18-S22.	3.3	90
40	Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells. Haematologica, 2014, 99, 163-171.	1.7	90
41	MUC18, a member of the immunoglobulin superfamily, is expressed on bone marrow fibroblasts and a subset of hematological malignancies. Leukemia, 1998, 12, 414-421.	3.3	88
42	4 Adhesion molecules in haemopoiesis. Best Practice and Research: Clinical Haematology, 1997, 10, 485-505.	1.1	86
43	Immunoselected STRO-3+mesenchymal precursor cells and restoration of the extracellular matrix of degenerate intervertebral discs. Journal of Neurosurgery: Spine, 2012, 16, 479-488.	0.9	85
44	Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica, 2010, 95, 776-784.	1.7	84
45	Tunable Biomimetic Hydrogels from Silk Fibroin and Nanocellulose. ACS Sustainable Chemistry and Engineering, 2020, 8, 2375-2389.	3.2	84
46	Identification of a Common Gene Expression Signature Associated with Immature Clonal Mesenchymal Cell Populations Derived from Bone Marrow and Dental Tissues. Stem Cells and Development, 2010, 19, 1501-1510.	1.1	82
47	Brief Report: The Differential Roles of mTORC1 and mTORC2 in Mesenchymal Stem Cell Differentiation. Stem Cells, 2015, 33, 1359-1365.	1.4	82
48	The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. Journal of Bone and Mineral Research, 2010, 25, 1759-1770.	3.1	80
49	Facile and rapid ruthenium mediated photo-crosslinking of Bombyx mori silk fibroin. Journal of Materials Chemistry B, 2014, 2, 6259-6270.	2.9	80
50	EphB/ephrin-B interactions mediate human MSC attachment, migration and osteochondral differentiation. Bone, 2011, 48, 533-542.	1.4	79
51	Prenatally engineered autologous amniotic fluid stem cell-based heart valves in the fetal circulation. Biomaterials, 2012, 33, 4031-4043.	5.7	76
52	The Balance of Stromal BMP Signaling Mediated by GREM1 and ISLR Drives Colorectal Carcinogenesis. Gastroenterology, 2021, 160, 1224-1239.e30.	0.6	76
53	Imatinib as a potential antiresorptive therapy for bone disease. Blood, 2006, 107, 4334-4337.	0.6	74
54	Human mulipotential mesenchymal/stromal stem cells are derived from a discrete subpopulation of STRO-1bright/CD34 /CD45 /glycophorin-A-bone marrow cells. Haematologica, 2007, 92, 1707-1708.	1.7	72

#	Article	IF	CITATIONS
55	Heat Shock Protein-90 beta Is Expressed at the Surface of Multipotential Mesenchymal Precursor Cells: Generation of a Novel Monoclonal Antibody, STRO-4, With Specificity for Mesenchymal Precursor Cells From Human and Ovine Tissues. Stem Cells and Development, 2009, 18, 1253-1262.	1.1	70
56	Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis. Bone, 2002, 31, 448-456.	1.4	66
57	Genomic Profiling of Mesenchymal Stem Cells. Stem Cell Reviews and Reports, 2009, 5, 36-50.	5.6	66
58	Chronic Myeloid Leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 Activity. Leukemia, 2010, 24, 765-770.	3.3	64
59	Targeted Disruption of the CXCL12/CXCR4 Axis Inhibits Osteolysis in a Murine Model of Myeloma-Associated Bone Loss. Journal of Bone and Mineral Research, 2009, 24, 1150-1161.	3.1	63
60	Identification of Novel EZH2 Targets Regulating Osteogenic Differentiation in Mesenchymal Stem Cells and Development, 2016, 25, 909-921.	1.1	63
61	Reparative Effects of Allogeneic Mesenchymal Precursor Cells Delivered Transendocardially in Experimental Nonischemic Cardiomyopathy. JACC: Cardiovascular Interventions, 2010, 3, 974-983.	1.1	62
62	A Method to Isolate and Purify Human Bone Marrow Stromal Stem Cells. , 2008, 449, 45-57.		61
63	CD36/Fatty Acid Translocase in Rats: Distribution, Isolation from Hepatocytes, and Comparison with the Scavenger Receptor SR-B1. Laboratory Investigation, 2003, 83, 317-332.	1.7	60
64	Increased miR-155-5p and reduced miR-148a-3p contribute to the suppression of osteosarcoma cell death. Oncogene, 2016, 35, 5282-5294.	2.6	60
65	Effects of bound versus soluble pentosan polysulphate in PEC/HA-based hydrogels tailored for intervertebral disc regeneration. Biomaterials, 2014, 35, 1150-1162.	5.7	59
66	Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma. Clinical Cancer Research, 2015, 21, 3216-3229.	3.2	58
67	The role of the chemokine CXCL12 in osteoclastogenesis. Trends in Endocrinology and Metabolism, 2007, 18, 108-113.	3.1	56
68	Potential roles of growth factor PDGF-BB in the bony repair of injured growth plate. Bone, 2009, 44, 878-885.	1.4	55
69	Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion. Journal of Molecular Endocrinology, 2012, 48, 229-240.	1.1	55
70	EZH2 deletion in early mesenchyme compromises postnatal bone microarchitecture and structural integrity and accelerates remodeling. FASEB Journal, 2017, 31, 1011-1027.	0.2	55
71	NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells. Journal of Bone and Mineral Research, 2010, 25, 2126-2137.	3.1	54
72	Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo. Neoplasia, 2019, 21, 777-787.	2.3	53

ANDREW W C ZANNETTINO

#	Article	IF	CITATIONS
73	Specific functions of TET1 and TET2 in regulating mesenchymal cell lineage determination. Epigenetics and Chromatin, 2019, 12, 3.	1.8	53
74	Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia, 2009, 23, 994-997.	3.3	52
75	Microarray expression analysis of genes and pathways involved in growth plate cartilage injury responses and bony repair. Bone, 2012, 50, 1081-1091.	1.4	52
76	Plasma Adiponectin Levels Are Markedly Elevated in Imatinib-Treated Chronic Myeloid Leukemia (CML) Patients: A Mechanism for Improved Insulin Sensitivity in Type 2 Diabetic CML Patients?. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3763-3767.	1.8	51
77	Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche?. Blood Cancer Journal, 2012, 2, e91-e91.	2.8	51
78	mTORC1 Plays an Important Role in Skeletal Development by Controlling Preosteoblast Differentiation. Molecular and Cellular Biology, 2017, 37, .	1.1	51
79	Application of Autologous Bone Marrow Derived Mesenchymal Stem Cells to an Ovine Model of Growth Plate Cartilage Injury. The Open Orthopaedics Journal, 2010, 4, 204-210.	0.1	50
80	CD164 Monoclonal Antibodies That Block Hemopoietic Progenitor Cell Adhesion and Proliferation Interact with the First Mucin Domain of the CD164 Receptor. Journal of Immunology, 2000, 165, 840-851.	0.4	48
81	Inhibition of c-fms by Imatinib: Expanding the Spectrum of Treatment. Cell Cycle, 2005, 4, 851-853.	1.3	48
82	Histone deacetylases (HDAC) in physiological and pathological bone remodelling. Bone, 2017, 95, 162-174.	1.4	47
83	Therapeutic effects of human STROâ€3â€selected mesenchymal precursor cells and their soluble factors in experimental myocardial ischemia. Journal of Cellular and Molecular Medicine, 2011, 15, 2117-2129.	1.6	46
84	Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment. Internal Medicine Journal, 2009, 39, 304-316.	0.5	44
85	The revival of dithiocarbamates: from pesticides to innovative medical treatments. IScience, 2021, 24, 102092.	1.9	44
86	The immunoreceptor tyrosine-based activation motif (ITAM) -related factors are increased in synovial tissue and vasculature of rheumatoid arthritic joints. Arthritis Research and Therapy, 2012, 14, R245.	1.6	43
87	Impact of Timing and Dose of Mesenchymal Stromal Cell Therapy in a Preclinical Model of Acute Myocardial Infarction. Journal of Cardiac Failure, 2013, 19, 342-353.	0.7	43
88	Imatinib mesylate causes growth plate closure in vivo. Leukemia, 2009, 23, 2155-2159.	3.3	42
89	EphB4 enhances the process of endochondral ossification and inhibits remodeling during bone fracture repair. Journal of Bone and Mineral Research, 2013, 28, 926-935.	3.1	42
90	Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma. Cancer Letters, 2015, 357, 160-169.	3.2	42

#	Article	IF	CITATIONS
91	Isolation of a Human Homolog of Osteoclast Inhibitory Lectin That Inhibits the Formation and Function of Osteoclasts. Journal of Bone and Mineral Research, 2003, 19, 89-99.	3.1	41
92	Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer. Molecular Cancer Therapeutics, 2009, 8, 2969-2980.	1.9	41
93	HIF-2α Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1. Cancer Research, 2017, 77, 5452-5463.	0.4	41
94	The efficacy of allogeneic mesenchymal precursor cells for the repair of an ovine tibial segmental defect. Veterinary and Comparative Orthopaedics and Traumatology, 2011, 24, 113-121.	0.2	40
95	TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis. Arthritis Research and Therapy, 2011, 13, R51.	1.6	40
96	Molecular cloning of the cell surface antigen identified by the osteoprogenitor-specific monoclonal antibody, HOP-26. Journal of Cellular Biochemistry, 2003, 89, 56-66.	1.2	38
97	Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress. Oncotarget, 2017, 8, 43602-43616.	0.8	37
98	SAMSN1 Is a Tumor Suppressor Gene in Multiple Myeloma. Neoplasia, 2014, 16, 572-585.	2.3	36
99	Hypoxia inducible factor (HIF)-2α accelerates disease progression in mouse models of leukemia and lymphoma but is not a poor prognosis factor in human AML. Leukemia, 2015, 29, 2075-2085.	3.3	36
100	Allogeneic Mesenchymal Precursor Cells Promote Healing in Postero-lateral Annular Lesions and Improve Indices of Lumbar Intervertebral Disc Degeneration in an Ovine Model. Spine, 2016, 41, 1331-1339.	1.0	36
101	Fragmentation of tissue-resident macrophages during isolation confounds analysis of single-cell preparations from mouse hematopoietic tissues. Cell Reports, 2021, 37, 110058.	2.9	36
102	Relationship between Novel Isoforms, Functionally Important Domains, and Subcellular Distribution of CD164/Endolyn. Journal of Biological Chemistry, 2001, 276, 2139-2152.	1.6	35
103	Novel mesenchymal and haematopoietic cell isoforms of the SHP-2 docking receptor, PZR: identification, molecular cloning and effects on cell migration. Biochemical Journal, 2003, 370, 537-549.	1.7	35
104	Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. Journal of Cellular Physiology, 2005, 203, 573-582.	2.0	34
105	Cervical motion preservation using mesenchymal progenitor cells and pentosan polysulfate, a novel chondrogenic agent: preliminary study in an ovine model. Neurosurgical Focus, 2010, 28, E4.	1.0	34
106	Tumor Angiogenesis Is Associated with Plasma Levels of Stromal-Derived Factor-1α in Patients with Multiple Myeloma. Clinical Cancer Research, 2006, 12, 6973-6977.	3.2	33
107	Comparative Assessment of the Osteoconductive Properties of Different BiomaterialsIn VivoSeeded with Human or Ovine Mesenchymal Stem/Stromal Cells. Tissue Engineering - Part A, 2010, 16, 3579-3587.	1.6	33
108	Decidua Parietalis-Derived Mesenchymal Stromal Cells Reside in a Vascular Niche Within the Choriodecidua. Reproductive Sciences, 2012, 19, 1302-1314.	1.1	33

ANDREW W C ZANNETTINO

#	Article	IF	CITATIONS
109	The Mesenchymal Precursor Cell Marker Antibody STRO-1 Binds to Cell Surface Heat Shock Cognate 70. Stem Cells, 2017, 35, 940-951.	1.4	33
110	Apo2L/TRAIL Inhibits Tumor Growth and Bone Destruction in a Murine Model of Multiple Myeloma. Clinical Cancer Research, 2009, 15, 1998-2009.	3.2	32
111	Intramyocardial Navigation and Mapping for Stem Cell Delivery. Journal of Cardiovascular Translational Research, 2010, 3, 135-146.	1.1	31
112	Assessment of myocardial fibrosis by endoventricular electromechanical mapping in experimental nonischemic cardiomyopathy. International Journal of Cardiovascular Imaging, 2011, 27, 25-37.	0.7	31
113	Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo. Experimental Cell Research, 2015, 332, 24-38.	1.2	31
114	A non-canonical role for desmoglein-2 in endothelial cells: implications for neoangiogenesis. Angiogenesis, 2016, 19, 463-486.	3.7	31
115	PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. Journal of Hematology and Oncology, 2015, 8, 106.	6.9	29
116	EphB4 Expressing Stromal Cells Exhibit an Enhanced Capacity for Hematopoietic Stem Cell Maintenance. Stem Cells, 2015, 33, 2838-2849.	1.4	29
117	The effect of the dual PI3K and <scp>mTOR</scp> inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma. European Journal of Haematology, 2015, 94, 343-354.	1.1	29
118	3D printing of a thermosensitive hydrogel for skin tissue engineering: A proof of concept study. Bioprinting, 2020, 19, e00089.	2.9	29
119	Translation of remote control regenerative technologies for bone repair. Npj Regenerative Medicine, 2018, 3, 9.	2.5	28
120	Optimization of the Cardiovascular Therapeutic Properties of Mesenchymal Stromal/Stem Cells–Taking the Next Step. Stem Cell Reviews and Reports, 2013, 9, 281-302.	5.6	27
121	Anticancer efficacy of the hypoxiaâ€activated prodrug evofosfamide (THâ€302) in osteolytic breast cancer murine models. Cancer Medicine, 2016, 5, 534-545.	1.3	27
122	The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation. Blood Cancer Journal, 2011, 1, e2-e2.	2.8	25
123	Near Superhydrophobic Fibrous Scaffold for Endothelialization: Fabrication, Characterization and Cellular Activities. Biomacromolecules, 2013, 14, 3850-3860.	2.6	25
124	Therapeutic targeting of N adherin is an effective treatment for multiple myeloma. British Journal of Haematology, 2015, 171, 387-399.	1.2	25
125	Engineering DN hydrogels from regenerated silk fibroin and poly(N-vinylcaprolactam). Journal of Materials Chemistry B, 2016, 4, 5519-5533.	2.9	25
126	An Ovine Model of Toxic, Nonischemic Cardiomyopathy—Assessment by Cardiac Magnetic Resonance Imaging. Journal of Cardiac Failure, 2008, 14, 785-795.	0.7	24

#	Article	IF	CITATIONS
127	Prospective Histomorphometric and DXA Evaluation of Bone Remodeling in Imatinib-Treated CML Patients: Evidence for Site-Specific Skeletal Effects. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 67-76.	1.8	24
128	The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine-expressing myeloma cells. British Journal of Haematology, 2017, 177, 423-440.	1.2	24
129	Adoptive transfer of exÂvivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer. Cancer Letters, 2017, 386, 141-150.	3.2	24
130	A Comparison of Mesenchymal Precursor Cells and Amnion Epithelial Cells for Enhancing Cervical Interbody Fusion in an Ovine Model. Neurosurgery, 2011, 68, 1025-1035.	0.6	23
131	Circulating <scp>N</scp> â€cadherin levels are a negative prognostic indicator in patients with multiple myeloma. British Journal of Haematology, 2013, 161, 499-507.	1.2	23
132	Mesenchymal progenitor cells primed with pentosan polysulfate promote lumbar intervertebral disc regeneration in an ovine model of microdiscectomy. Spine Journal, 2018, 18, 491-506.	0.6	23
133	hTERT Transcription Is Repressed by Cbfa1 in Human Mesenchymal Stem Cell Populations. Journal of Bone and Mineral Research, 2007, 22, 897-906.	3.1	22
134	Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma. Cancer Letters, 2020, 475, 99-108.	3.2	22
135	Evidence for reduced bone formation surface relative to bone resorption surface in female femoral fragility fracture patients. Bone, 2006, 39, 1226-1235.	1.4	20
136	The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells. Blood, 2010, 116, 2776-2778.	0.6	20
137	Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer. International Journal of Oncology, 2014, 45, 532-540.	1.4	20
138	Incremental benefits of repeated mesenchymal stromal cell administration compared with solitary intervention after myocardial infarction. Cytotherapy, 2014, 16, 460-470.	0.3	20
139	Twist-1 Enhances Bone Marrow Mesenchymal Stromal Cell Support of Hematopoiesis by Modulating CXCL12 Expression. Stem Cells, 2016, 34, 504-509.	1.4	20
140	EphA5 and EphA7 forward signaling enhances human hematopoietic stem and progenitor cell maintenance, migration, and adhesion via Rac1 activation. Experimental Hematology, 2017, 48, 72-78.	0.2	20
141	Methods for the Purification and Characterization of Human Adipose-Derived Stem Cells. Methods in Molecular Biology, 2011, 702, 109-120.	0.4	20
142	Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo. Journal of Bone and Mineral Research, 2011, 26, 630-643.	3.1	19
143	Protein Kinase Activity of Phosphoinositide 3-Kinase Regulates Cytokine-Dependent Cell Survival. PLoS Biology, 2013, 11, e1001515.	2.6	19
144	Management of systemic <scp>AL</scp> amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, 2015, 45, 371-382.	0.5	19

#	Article	IF	CITATIONS
145	Loss of ephrinB1 in osteogenic progenitor cells impedes endochondral ossification and compromises bone strength integrity during skeletal development. Bone, 2016, 93, 12-21.	1.4	19
146	Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. Internal Medicine Journal, 2017, 47, 938-951.	0.5	19
147	Does Apo2L/TRAIL play any physiologic role in osteoclastogenesis?. Blood, 2008, 111, 5411-5412.	0.6	18
148	Engineering Interaction between Bone Marrow Derived Endothelial Cells and Electrospun Surfaces for Artificial Vascular Graft Applications. Biomacromolecules, 2014, 15, 1276-1287.	2.6	18
149	DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment. Neoplasia, 2017, 19, 972-981.	2.3	18
150	Interaction of Platelets with Poly(vinylidene fluoride- <i>co</i> -hexafluoropropylene) Electrospun Surfaces. Biomacromolecules, 2014, 15, 744-755.	2.6	17
151	Bone Marrow Recovery by Morphometry during Induction Chemotherapy for Acute Lymphoblastic Leukemia in Children. PLoS ONE, 2015, 10, e0126233.	1.1	17
152	The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma. Leukemia Research, 2015, 39, 380-387.	0.4	17
153	Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma. British Journal of Haematology, 2017, 178, 196-208.	1.2	17
154	mTORC1 plays an important role in osteoblastic regulation of B-lymphopoiesis. Scientific Reports, 2018, 8, 14501.	1.6	17
155	Enhanced multi-lineage differentiation of human mesenchymal stem/stromal cells within poly(<i>N</i> -isopropylacrylamide-acrylic acid) microgel-formed three-dimensional constructs. Journal of Materials Chemistry B, 2018, 6, 1799-1814.	2.9	16
156	Fabrication of a Cartilage Patch by Fusing Hydrogel-Derived Cell Aggregates onto Electrospun Film. Tissue Engineering - Part A, 2020, 26, 863-871.	1.6	16
157	The osteoprogenitor-specific loss of ephrinB1 results in an osteoporotic phenotype affecting the balance between bone formation and resorption. Scientific Reports, 2018, 8, 12756.	1.6	15
158	Peroxidase enzymes inhibit osteoclast differentiation and bone resorption. Molecular and Cellular Endocrinology, 2017, 440, 8-15.	1.6	14
159	Loss of EfnB1 in the osteogenic lineage compromises their capacity to support hematopoietic stem/progenitor cell maintenance. Experimental Hematology, 2019, 69, 43-53.	0.2	14
160	Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis. Cellular and Molecular Life Sciences, 2021, 78, 249-270.	2.4	14
161	Reduced Activity of the OCT-1 Protein in Primitive CML Cells: A Likely Determinant of Stem Cell Resistance in Imatinib Treated CML Patients. Blood, 2008, 112, 196-196.	0.6	14
162	Current and Future Applications for Stem Cell Therapies in Spine Surgery. Current Stem Cell Research and Therapy, 2013, 8, 381-393.	0.6	14

#	Article	IF	CITATIONS
163	OCT-1 function varies with cell lineage but is not influenced by BCR-ABL. Haematologica, 2011, 96, 213-220.	1.7	13
164	Development of Novel Monoclonal Antibodies that Define Differentiation Stages of Human Stromal (Mesenchymal) Stem Cells. Molecules and Cells, 2011, 32, 133-142.	1.0	13
165	Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the <scp>M</scp> yeloma <scp>F</scp> oundation of <scp>A</scp> ustralia <scp>M</scp> edical and <scp>S</scp> cientific <scp>A</scp> dvisory <scp>G</scp> roup. Internal Medicine Journal. 2015, 45, 94-105.	0.5	13
166	Tyrosine kinase receptor c-ros-oncogene 1 mediates TWIST-1 regulation of human mesenchymal stem cell lineage commitment. Bone, 2017, 94, 98-107.	1.4	13
167	Osteocalcinâ€dependent regulation of glucose metabolism and fertility: Skeletal implications for the development of insulin resistance. Journal of Cellular Physiology, 2018, 233, 3769-3783.	2.0	13
168	Potential Applications for Using Stem Cells in Spine Surgery. Current Stem Cell Research and Therapy, 2010, 5, 345-355.	0.6	13
169	miRNA-376c-3p Mediates TWIST-1 Inhibition of Bone Marrow-Derived Stromal Cell Osteogenesis and Can Reduce Aberrant Bone Formation of TWIST-1 Haploinsufficient Calvarial Cells. Stem Cells and Development, 2018, 27, 1621-1633.	1.1	11
170	HOPX regulates bone marrow-derived mesenchymal stromal cell fate determination via suppression of adipogenic gene pathways. Scientific Reports, 2020, 10, 11345.	1.6	11
171	Macrophages in multiple myeloma: key roles and therapeutic strategies. Cancer and Metastasis Reviews, 2021, 40, 273-284.	2.7	11
172	Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells <i>in vivo</i> . Haematologica, 2021, 106, 3176-3187.	1.7	11
173	Chondrogenic preconditioning of mesenchymal stem/stromal cells within a magnetic scaffold for osteochondral repair. Biofabrication, 2022, 14, 025020.	3.7	11
174	Reticulin fibres anchor leukaemic blasts in the marrow of patients with acute lymphoblastic leukaemia. Medical Hypotheses, 2011, 77, 333-335.	0.8	10
175	Fabrication and characterisation of an electrospun tubular 3D scaffold platform of poly(vinylidene) Tj ETQq1 1).784314 r 1.9	gBT /Overloc 10
	Biomaterials Science, Polymer Edition, 2014, 25, 2023-2041.		
176	Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, 2017, 47, 35-49.	0.5	10
177	Allogeneic primary mesenchymal stem/stromal cell aggregates within poly(N-isopropylacrylamide-co-acrylic acid) hydrogel for osteochondral regeneration. Applied Materials Today, 2020, 18, 100487.	2.3	10
178	Anticancer efficacy of the hypoxiaâ€activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma. Cancer Medicine, 2017, 6, 2164-2176.	1.3	9
179	Hydrogel-based preparation of cell aggregates for biomedical applications. Applied Materials Today, 2020, 20, 100747.	2.3	9
180	The stem cell revolution: on the role of CD164 as a human stem cell marker. Npj Regenerative Medicine, 2021, 6, 33.	2.5	9

#	Article	IF	CITATIONS
181	Desmogleinâ€2 expression is an independent predictor of poor prognosis patients with multiple myeloma. Molecular Oncology, 2022, 16, 1221-1240.	2.1	9
182	Myeloma-Induced Alloreactive T Cells Arising in Myeloma-Infiltrated Bones Include Double-Positive CD8+CD4+T Cells: Evidence from Myeloma-Bearing Mouse Model. Journal of Immunology, 2011, 187, 3987-3996.	0.4	8
183	Pentosan polysulfate binds to STRO-1+ mesenchymal progenitor cells, is internalized, and modifies gene expression: a novel approach of pre-programing stem cells for therapeutic application requiring their chondrogenesis. Stem Cell Research and Therapy, 2017, 8, 278.	2.4	8
184	Tyrosine kinase receptor c-ros-oncogene 1 inhibition alleviates aberrant bone formation of TWIST-1 haploinsufficient calvarial cells from Saethre-Chotzen syndrome patients. Journal of Cellular Physiology, 2018, 233, 7320-7332.	2.0	8
185	Conditional knockout of ephrinB1 in osteogenic progenitors delays the process of endochondral ossification during fracture repair. Bone, 2020, 132, 115189.	1.4	8
186	Cardiac magnetic resonance, transthoracic and transoesophageal echocardiography: a comparison of inÂvivo assessment of ventricular function in rats. Laboratory Animals, 2013, 47, 291-300.	0.5	7
187	Targeted Disruption of Bone Marrow Stromal Cell-Derived Gremlin1 Limits Multiple Myeloma Disease Progression In Vivo. Cancers, 2020, 12, 2149.	1.7	6
188	Tumour Dissemination in Multiple Myeloma Disease Progression and Relapse: A Potential Therapeutic Target in High-Risk Myeloma. Cancers, 2020, 12, 3643.	1.7	6
189	LCRFâ€0006, a small molecule mimetic of the Nâ€cadherin antagonist peptide ADHâ€1, synergistically increases multiple myeloma response to bortezomib. FASEB BioAdvances, 2020, 2, 339-353.	1.3	6
190	Specificity and Functional Effects of Antibodies to Human Stem Cell Factor. Growth Factors, 1997, 14, 67-79.	0.5	5
191	Circulating levels of TWEAK correlate with bone erosion in multiple myeloma patients. British Journal of Haematology, 2010, 150, 373-376.	1.2	5
192	The mTORC1 complex in pre-osteoblasts regulates whole-body energy metabolism independently of osteocalcin. Bone Research, 2021, 9, 10.	5.4	5
193	A novel CD44 antibody identifies an epitope that is aberrantly expressed on acute lymphoblastic leukaemia cells. Immunology and Cell Biology, 2003, 81, 311-319.	1.0	4
194	Osteopontin in the pathophysiology of obesity: Is Opn a fat cell foe?. Obesity Research and Clinical Practice, 2018, 12, 249-250.	0.8	4
195	CMTM8 Is a Suppressor of Human Mesenchymal Stem Cell Osteogenic Differentiation and Promoter of Proliferation Via EGFR Signaling. Stem Cells and Development, 2020, 29, 823-834.	1.1	4
196	Characterization of the role of Samsn1 loss in multiple myeloma development. FASEB BioAdvances, 2020, 2, 554-572.	1.3	3
197	PO-Related Protein Accelerates Human Mesenchymal Stromal Cell Migration by Modulating VLA-5 Interactions with Fibronectin. Cells, 2020, 9, 1100.	1.8	3
198	Doxorubicin overcomes resistance to drozitumab by antagonizing Inhibitor of Apoptosis Proteins (IAPs). Anticancer Research, 2014, 34, 7007-20.	0.5	3

#	Article	IF	CITATIONS
199	GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice. PLoS ONE, 2020, 15, e0228408.	1.1	2
200	CKLF and IL1B transcript levels at diagnosis are predictive of relapse in children with preâ€B ell acute lymphoblastic leukaemia. British Journal of Haematology, 2021, 193, 171-175.	1.2	2
201	Plant-derived soybean peroxidase stimulates osteoblast collagen biosynthesis, matrix mineralization, and accelerates bone regeneration in a sheep model. Bone Reports, 2021, 14, 101096.	0.2	2
202	Multipotential Mesenchymal Stromal/Stem Cells in Skeletal Tissue Repair. , 2013, , 82-102.		2
203	Using genomics to better define high-risk MGUS/SMM patients. Oncotarget, 2018, 9, 36549-36550.	0.8	2
204	A novel epitope of CD59 expressed by primitive human hematopoietic progenitors. Experimental Hematology, 2001, 29, 1474-1483.	0.2	1
205	An In Vitro Osteoclast-Forming Assay to Measure Myeloma Cell-Derived Osteoclast-Activating Factors. , 2005, 113, 245-256.		1
206	Home Is Where the Heart Is: Via the FROUNT. Cell Stem Cell, 2008, 2, 513-514.	5.2	1
207	Deletion of <i>Rptor</i> in Preosteoblasts Reveals a Role for the Mammalian Target of Rapamycin Complex 1 (<scp>mTORC1)</scp> Complex in Dietaryâ€Induced Changes to Bone Mass and Glucose Homeostasis in Female Mice. JBMR Plus, 2021, 5, e10486.	1.3	1
208	Bone Loss, Cancer Mediated. , 2008, , 382-385.		1
209	Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia. Internal Medicine Journal, 2021, 51, 1707-1712.	0.5	1
210	Co-fuse: a new class discovery analysis tool to identify and prioritize recurrent fusion genes from RNA-sequencing data. Molecular Genetics and Genomics, 2018, 293, 1217-1229.	1.0	0
211	Ethylene Diamine Tetra Acetic Acid (EDTA) Decalcification of Paediatric Bone Marrow Trephines In a Diagnostic Laboratory. Blood, 2010, 116, 2566-2566.	0.6	0
212	Hypoxia Inducible Factor (HIF)-2α Enhances Proliferation Of Malignant Hematopoietic Cells In The Hypoxic Malignant Bone Marrow. Blood, 2013, 122, 2895-2895.	0.6	0